country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

106 Results for "

IL-23

" in MedChemExpress (MCE) Product Catalog:

Products (106)

Sort by :

Categories

By Targets

Species:

Tags:

Sources:

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

Apilimod

47 Publications Verification

Cat. No.: HY-14644

CAS No.: 541550-19-0

Purity: 99.80%

Synonyms: STA 5326; LAM-002A free base; AIT-101

Target:

Interleukin Related PIKfyve

Research Areas:

Inflammation/Immunology Cancer

Apilimod (STA 5326) is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC₅₀s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively . Apilimod is a potent and highly selective PIKfyve inhibitor.

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Apilimod mesylate

47 Publications Verification

Cat. No.: HY-14644A

CAS No.: 870087-36-8

Purity: 99.83%

Synonyms: STA 5326 mesylate; LAM-002A; AIT-101 mesylate

Target:

Interleukin Related PIKfyve

Research Areas:

Inflammation/Immunology Cancer

Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC₅₀s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively . Apilimod is a potent and highly selective PIKfyve inhibitor.

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Deucravacitinib

38 Cited Publications

Cat. No.: HY-117287

CAS No.: 1609392-27-9

Purity: 99.87%

Synonyms: BMS-986165

Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC₅₀ of 0.2 nM and a K_i of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

APY0201

7 Cited Publications

Cat. No.: HY-15982

CAS No.: 1232221-74-7

Target:

PIKfyve Interleukin Related

Research Areas:

Inflammation/Immunology

APY0201 is a potent PIKfyve inhibitor, which inhibits the conversion of PtdIns3P to PtdIns(3,5)P₂ in the presence of in the presence of [ ³³P]ATP with an IC₅₀ of 5.2 nM. APY0201 also inhibits IL-12/IL-23 production.

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Ustekinumab

4 Cited Publications

Cat. No.: HY-P9909

CAS No.: 815610-63-0

Synonyms: CNTO-1275; L04AC05; TT-20

Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Irsogladine

3 Cited Publications

Cat. No.: HY-B0327

CAS No.: 57381-26-7

Synonyms: Dicloguamine

Target:

Phosphodiesterase (PDE) NF-κB AP-1 TRP Channel Interleukin Related

Research Areas:

Inflammation/Immunology Cancer

Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and K_ATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer ^[5][6] .

Compare